Displaying drugs 10976 - 11000 of 11581 in total
Codrituzumab
Codrituzumab is under investigation in clinical trial NCT01507168 (A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma).
Investigational
Matched Description: … Codrituzumab is under investigation in clinical trial NCT01507168 (A Study of RO5137382 (GC33) in Patients …
2-fluorofucose
2-fluorofucose is under investigation in clinical trial NCT02952989 (A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors).
Investigational
Matched Description: … 2-fluorofucose is under investigation in clinical trial NCT02952989 (A Safety Study of SGN-2FF for Patients …
Dinalbuphine sebacate
Dinalbuphine sebacate is under investigation in clinical trial NCT02468128 (A Study of Intramuscular Sebacoyl Dinalbuphine Ester for Post-Hemorrhoidectomy Pain Management).
Investigational
Matched Description: … Dinalbuphine sebacate is under investigation in clinical trial NCT02468128 (A Study of Intramuscular …
Recombinant human plasma gelsolin
Plasma gelsolin (pGSN) is a protein found in the blood of healthy individuals which scavenges compounds left over from damaged tissues.
Investigational
Matched Description: … Plasma gelsolin (pGSN) is a protein found in the blood of healthy individuals which scavenges compounds …
Ifidancitinib
Ifidancitinib is under investigation in clinical trial NCT03585296 (A Study of ATI-502 Topical Solution for the Treatment of Atopic Dermatitis).
Investigational
Matched Description: … Ifidancitinib is under investigation in clinical trial NCT03585296 (A Study of ATI-502 Topical Solution …
Emprumapimod
Emprumapimod is a potent, orally active and selective inhibitor of p38α mitogen-activated kinase inhibitor. It was investigated for dilated cardiomyopathy.
Investigational
Matched Description: … Emprumapimod is a potent, orally active and selective inhibitor of p38α mitogen-activated kinase inhibitor …
SPL23-2
SPL23-2 is an antisense oligonucleotide (ASO) targeting the W1282X nonsense mutation associated with a severe form of cystic fibrosis.
Investigational
Matched Description: … SPL23-2 is an antisense oligonucleotide (ASO) targeting the W1282X nonsense mutation associated with a …
Mitiglinide
Mitiglinide is a drug for the treatment of type 2 diabetes. It may stimulate insulin secretion in beta-cells by closing off ATP dependant potassium ion channels.
Investigational
Matched Description: … Mitiglinide is a drug for the treatment of type 2 diabetes. …
NGX267
NGX267 is a muscarinic agonist. It is developed for the treatment of Alzheimer’s disease and has shown the potential to both reduce symptoms and slow disease progression.
Investigational
Matched Description: … NGX267 is a muscarinic agonist. …
PF-06282999
Pf 06282999 is under investigation in clinical trial NCT01626976 (A Study To Assess The Safety, Tolerability And Pharmacokinetics Of PF-06282999 Administered Orally In Healthy Adult Subjects).
Investigational
Matched Description: … Pf 06282999 is under investigation in clinical trial NCT01626976 (A Study To Assess The Safety, Tolerability …
JNJ-42396302
Jnj 42396302 is under investigation in clinical trial NCT01732237 (A Study to Investigate the Pharmacokinetics of JNJ-42396302, JNJ-53773187 and JNJ-42692507 in Healthy Male Participants).
Investigational
Matched Description: … Jnj 42396302 is under investigation in clinical trial NCT01732237 (A Study to Investigate the Pharmacokinetics …
Reposal
Reposal is a barbiturate derivative invented in the 1960s in Denmark that has sedative, hypnotic and anticonvulsant properties. It was used primarily in the treatment of insomnia.
Experimental
Matched Description: … Reposal is a barbiturate derivative invented in the 1960s in Denmark that has sedative, hypnotic and …
Elenbecestat
Elenbecestat is under investigation in clinical trial NCT02956486 (A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease).
Investigational
Matched Description: … Elenbecestat is under investigation in clinical trial NCT02956486 (A 24-Month Study to Evaluate the Efficacy …
Giripladib
Giripladib is under investigation in clinical trial NCT00396955 (A Study Comparing 4 Dose Regimens of PLA-695, Naproxen, and Placebo In Subjects With Osteoarthritis Of The Knee).
Investigational
Matched Description: … Giripladib is under investigation in clinical trial NCT00396955 (A Study Comparing 4 Dose Regimens of …
CYNK-001
CYNK-001 is a novel allogenic off-the-shelf natural killer (NK) cell therapy originating from human placental CD34+ hematopoietic stem cells and enriched with CD56+/CD3-.
Investigational
Matched Description: … CYNK-001 is a novel allogenic off-the-shelf natural killer (NK) cell therapy originating from human placental …
Birtamimab
Birtamimab is under investigation in clinical trial NCT02312206 (The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis).
Investigational
Matched Description: … Birtamimab is under investigation in clinical trial NCT02312206 (The VITAL Amyloidosis Study, a Global …
IO-202
IO-202 is a first-in-class antibody targeting the Leukocyte Immunoglobulin-Like Receptor subfamily B (LILRB) member 4 (LILRB4). It is being investigated in cancers.
Investigational
Matched Description: … IO-202 is a first-in-class antibody targeting the Leukocyte Immunoglobulin-Like Receptor subfamily B …
Reloxiliase
Reloxiliase is a first-in-class, oral crystalline formulation of the oxalate-specific, microbial enzyme oxalate decarboxylase. It is being investigated for the treatment of hyperoxaluria.
Investigational
Matched Description: … Reloxiliase is a first-in-class, oral crystalline formulation of the oxalate-specific, microbial enzyme …
BMS-564929
BMS-564929 is an investigational therapeutic agent built to be a selective androgen receptor modulator (SARM). So far, it has been developed by Bristol-Myers Squibb for the symptomatic treatment of andropause.
Experimental
Matched Description: … BMS-564929 is an investigational therapeutic agent built to be a selective androgen receptor modulator …
Indium In-111 imciromab pentetate
Indium In-111 imciromab pentetate is a mouse monoclonal antibody labelled with the radioisotope Indium-111 which was used for cardiac imaging under the trade name Myoscint, but was withdrawn in 1993.
Withdrawn
Matched Description: … Indium In-111 imciromab pentetate is a mouse monoclonal antibody labelled with the radioisotope Indium …
TBX-3400
TBX-3400 is an investigational cell-based immunotherapy consisting of autologous peripheral blood mononuclear cells (PBMCs) treated ex vivo with TBX-4000, which is a recombinant TAT-MYC fusion protein.[L44281,L44286]
Investigational
Matched Description: … consisting of autologous peripheral blood mononuclear cells (PBMCs) treated ex vivo with TBX-4000, which is a …
Virulizin
Investigational
DOTMP SM-153
Investigational
Bevantolol
Bevantolol is a beta-1 adrenoceptor antagonist that has been shown to be as effective as other beta blockers for the treatment of angina pectoris and hypertension. Mechanism of Action Animal experiments confirm both agonist and antagonist effects on alpha-receptors, in addition to antagonist activity at beta-1 receptors.
Experimental
Matched Description: … Bevantolol is a beta-1 adrenoceptor antagonist that has been shown to be as effective as other beta blockers …
Garcinia gummi-gutta fruit
Garcinia gummi-gutta fruit is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Experimental
Matched Description: … Garcinia gummi-gutta fruit is a plant/plant extract used in some OTC (over-the-counter) products. …
Displaying drugs 10976 - 11000 of 11581 in total